@OncEd Presents Dr. Wendie Den Brok – Survival of Metastatic HR Positive/HER2 Negative, Triple Negative and HER2 Positive Breast Cancer…
Browsing: Acute Lymphoblastic Leukemia
@OncEd Presents Dr. Stephen Chia – Treating Advanced Breast Cancer in the Genomic Era – Best of Oncology West 2015
@OncEd Presents Dr. Philip Halloran – Identifying T Cell-Mediated Inflammation in Tissue by Molecular Phenotyping: Lessons from Kidney Transplantation -…
@OncEd Presents Dr. David Hogg & Dr. Xinni Song – Addressing Key Questions in immune-Oncology – Canadian Melanoma Conference 2015
@OncEd Presents Dr. David Zloty – Mohs Surgery for Melanoma and Merkel – Canadian Melanoma Conference 2015
@OncEd Presents Dr. Heidi Wat – A Seven-Year analysis of Mitotic Rate & Sentinel Lymph Node Biopsy Status in Patients…
@OncEd Presents Dr. Chloé Ward – The Rate of Missed Melanoma in Sentinel Node Negative Patients: The Ottawa Experience -…
@OncEd Presents Dr. Claire Temple-Oberle – Interleukin-2 for In transit Melanoma – Canadian Melanoma Conference 2015
@OncEd Presents Dr. Jeff Sosman – Treatment of Non-BRAFV600E Melanoma With Targeted Therapy – Canadian Melanoma Conference 2015
@OncEd Presents Dr. Merrick Ross – Intralesional Therapy For Melanoma – Canadian Melanoma Conference 2015
@OncEd Presents Dr. Merrick I. Ross – The Role of Neo-Adjuvant Therapy In Resectable Advanced Melanoma – Canadian Melanoma Conference…
@OncEd Presents Dr. Lynne Robertson – Population Screening For Melanoma – An Alberta Trial – Canadian Melanoma Conference 2015
@OncEd Presents Dr. Jason Rivers – Diagnostic Advances In Melanoma Detection – Canadian Melanoma Conference 2015
@OncEd Presents Dr. Dayna Miyashiro – Immunotherapy In Stage III Melanoma – Canadian Melanoma Conference 2015
@OncEd Presents Dr. Iren Kossintseva – Melanoma Inflammatory Response Signature – Canadian Melanoma Conference 2015
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Cheryl Vidall, Head of Nursing and Governance at Alcura…
@OncEd Presents Dr. David Hogg – Managing The Advanced Non-Melanoma Skin Cancers – Canadian Melanoma Conference 2015
@OncEd Presents Dr. Omid Hamid – PD1 Therapy and Biomarkers for Response – Canadian Melanoma Conference 2015
@OncEd Presents Dr. Axel Hauschild – Adjuvant Melanoma Treatment: Past, Present and Future – Canadian Melanoma Conference 2015
@OncEd Presents Dr. Femida Gwadry-Sridhar – Do We Really Need Big Data – Canadian Melanoma Conference 2015
@OncEd Presents Dr. Michael Davies – Clinical & Therapeutic Significance of the PI3K-AKT Pathway in Melanoma – Canadian Melanoma Conference…
@OncEd Presents Dr. Joel Claveau & Dr. Scott Ernst – A Practical Multi-Disciplinary Discussion of Challenging Cases in Melanoma -…
@OncEd Presents Dr. Marcus Butler – Immunotherapy for All: Next Steps When Current Therapies Fail – Canadian Melanoma Conference 2015
@OncEd Presents Dr. Marcus Butler – Immunotherapy for All: Next Steps When Current Therapies Fail – Canadian Melanoma Conference 2015
@OncEd Presents Dr. Boris Bastian – Towards an Integrated Taxonomy of Melanocytic Neoplasms – Canadian Melanoma Conference 2015
@OncEd Presents Dr. Eric Valli̬res РInnovation In Lung Cancer Surgery РCLCCO 2015
@OncEd Presents Dr. Glenwood Goss – Welcome From NCIC – CLCCO 2015
@OncEd Presents Dr. Sunil Verma – A National Strategy On Molecular Testing In NSCLC – CLCCO 2015
@OncEd Presents Dr. Yee Ung – A Canadian Radiation Oncologist Perspective – CLCCO 2015
@OncEd Presents Dr. Martin Reck – Lung Cancer: Today and Tomorrow – CLCCO 2015
@OncEd Presents Dr. Natasha Leigh – Third Generation EGFR TKI – CLCCO 2015
@OncEd Presents Dr. Gary Lee – Management of Malignant Pleural Effusions – CLCCO 2015
@OncEd Presents Dr. Rosalyn Juergens – Immunotherapy In NSCLC – CLCCO 2015
@OncEd Presents Dr. Laurie Gaspar – Lung Cancer Today: Maximizing the Therapeutic Ratio – CLCCO 2015
@OncEd Presents Dr. Krista Noonan – Debate: TKI in Adjuvant Setting For EGFR +VE Patients – No – CLCCO 2015
@OncEd Presents Dr. Jason Agulnik – Debate: TKI in Adjuvant Setting For EGFR +VE Patiens – Yes – CLCCO 2015
@OncEd Presents Dr. Paris Ingledew – Debate: Prophylactic Brain radiation For Extensive Stage Small Cell Cancer – Yes – CLCCO…
@OncEd Presents Dr. Patrick Cheung – Debate: Prophylactic Brain radiation For Extensive Stage Small Cell Cancer – No – CLCCO…
@OncEd Presents Dr. Charles Butts – Debate: Targeted Therapy Vs. Immunotherapy For First Line In SNCLC – NO – CLCCO…
@OncEd Presents Dr. Normand Blais – Debate: Targeted Therapy VS. Immunotherapy For First Line In NSCLC – YES – CLCCO…
@OncEd Presents Dr. Ross Camidge – The Changing World of Alk Mutations and Treatment – Lung Cancer – CLCCO 2015
@OncEd Presents Dr. Robert Kerbel – Anti-Angiogenic Therapies In Cancer – 2015
@OncEd Presents Dr. Alexander Lyon – Proteasome Inhibition – GCOS 2015
@OncEd Presents Dr. Lee Jones – Impairments In Cardiovascular Reserve Capacity And Efficacy of Exercise Countermeasures In Cancer – GCOS…
@OncEd Presents Dr. Michael Fradley – QT Prolongation And Other Electrophysiologic Considerations In Cancer Patients Undergoing Stem Cell therapy -…
@OncEd Presents Dr. Giorgio Minotti – Developing a Dedicated Cardio-Oncology Journal – GCOS 2015
@OncEd Presents Dr. Zaza Iakobishvili – Can Cardio-Oncology Deliver Improved Practice Internationally – GCOS 2015
@OncEd Presents Dr.Susan Dent – Establishing a Cardio-Oncology Clinic – GCOS 2015
@OncEd Presents Dr. Paul Richardson – Contemporary Treatment of Multiple Myeloma – GCOS 2015
@OncEd Presents Dr. Daniela Cardinale – The Practical Use of Cardiac Biomarkers – GCOS 2015
@OncEd Presents Dr. Ronald Schwartz – Leading Lessons of Radionuclide Angiocardiography – GCOS 2015
@OncEd Presents Dr. Anju Nohria – Autonomic Dysfunction in Patients Treated With Mediastinal or Neck Radiation – GCOS 2015
@OncEd Presents Dr. Dinesh Thavendiranathan – The Use of Strain And Newer Echocardiography Imaging Techniques – GCOS 2015
@OncEd Presents Dr. Sebastian Szmit – Is Dasatinib-Related Pulmonary Hypertension a Concern – GCOS 2015
@OncEd Presents Dr. Michael Savona – A Revolution in the treatment of Leukemia – GCOS 2015
@OncEd Presents Dr. Kathleen Pritchard – Comprehensive Cancer Care Includes Addressing Potential Impact of Cardiovascular Toxicity – GCOS 2015
@OncEd Presents Dr. Stephen Chia & Dr. Hope Rugo – Controversies and Challenges in Management of Metastatic Breast Cancer -…
@OncEd Presents Dinner Symposium: Shaping the Standard of Care – Best of Lung Cancer – 2015
@OncEd Presents Dr. Ros Juergens – Lung Cancer Immunotherapy: The Landscape in Canada – Best of Lung Cancer 2015
@OncEd Presents Dr. Scott Laurie – Squamous Cell Lung Update – Best of Lung Cancer – 2015
@OncEd Presents Dr. Barb Melosky – New Targets in NSCLC – Best of Lung Cancer – 2015
@OncEd Presents Case Based Discussions: Locally Advanced Lung Cancer – Best of Lung Cancer – 2015
@OncEd Presents Dr. Jeff Rothenstein – Advances in Alk-Positive NSCLC – Best of Lung Cancer – 2015
@OncEd Presents Dr. Ron Burkes – Adjuvant Treatment In NSCLC – Best of Lung Cancer – 2015
@OncEd Presents Dr. Heidi Roberts – Screening Update – Best of Lung Cancer – 2015
@OncEd Presents Lunch Symposium: Mapping Better Outcomes in Advanced NSCLC – Best Of Lung Cancer – 2015
@OncEd Presents Panel Discussion – Best Of Immuno-Oncology – 2015
@OncEd Presents Dr. Neil Berinstein – The Future Of Immuno-Oncology – Best Of Immuno-Oncology – 2015
@OncEd Presents Dr. Marcus Butler – T-Cell Transfer Therapies – Best Of Immuno-Oncology – 2015
@OncEd Presents Dr. Omid Hamid – Immunotherapy For Melanoma Patients – Best Of Immuno-Oncology – 2015
@OncEd Presents Dr. Natasha Leighl Immunotherapy in Lung Cancer – Best Of Immuno-Oncology 2015
@OncEd Presents Dr. Georg Bjarnason – Immuno-Oncology: Renal Cell – Best Of Immuno-Oncology 2015
@OncEd Presents Dr. Linh Nguyen – The Basic Premise of Immuno-Oncology – Best Of Immuno-Oncology
@OncEd Presents Panel Discussion: Workforce Planning in Oncology Across Canada – CAMO 2015
@OncEd Presents Dr. Jean Latreille – HR Planning in Oncology: Quebec – CAMO 2015
@OncEd Presents Dr. Leonard Kaizer – HR Planning in Oncology: Ontario – CAMO 2015
@OncEd Presents Dr. Chris Lee – HR Planning in Oncology: British Columbia – CAMO 2015
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Annie Young, SRN, PhD, Professor of Nursing, University of…
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Ali Hodge, Advanced Nurse Practitioner for Acute Oncology at…
From our Ask the Expert series, MPN expert Dr. Bart Scott from Seattle Cancer Care Alliance and the Fred Hutchinson…
From our Ask the Expert series, MPN expert Dr. Jamile Shammo, with Rush University Medical Center in Chicago, answers a…
Martin Wiseman, MD talks about how the environment we live in determines the patterns of cancer across the world. There…
@OncEd Presents Dr. Allan Covens – BRCA mutations in ovarian cancer
Robert Thomas, MbChb, MRCP, MD, FRCR, discusses the results of the Pomi-T clinical trial. The study focused on the effects…
Robert Thomas, MbChb, MRCP, MD, FRCR, discusses non-medicinal strategies to help cancer patients cope with cancer therapy side-effects. Prof. Robert…
Robert Thomas, MbChb, MRCP, MD, FRCR, discusses the importance of having a healthy diet for cancer patients. Prof. Robert Thomas…
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Margaret Oakes, Specialist Counselling Psychologist at Berkshire Healthcare NHS…
Does the development of resistant clones in multiple myeloma affect long-term treatment?
To what extent are you able to achieve long-term treatment goals in your patients with multiple myeloma?
Are there practical considerations for long-term treatment of multiple myeloma?
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Michael Mawhinney, doctoral research student, Oxford Brookes University, Oxford,…
Leading researcher Dr. Kanti Rai has devoted his career to understanding and classifying CLL. After Dr. Rais return from the…
From our latest Ask the Expert segment with MPN expert Dr. Bart Scott from Seattle Cancer Care Alliance (SCCA), he…
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Michelle Taylor, Clinical Nurse Specialist, of The Great Western…
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Debbie Gillen, of The Christie NHS Foundation Trust, Manchester,…
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Lisa Wells, Macmillan Lung Cancer Clinical Nurse Specialist, of…
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Andrew Turner, discusses a qualitative study of the self-management…
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Hilary Glen, MbChB, MSc, PhD, FRCP, of the Beatson…
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, which attracts cancer nurses from around the United Kingdom…
At the European Cancer Congress (ECC) 2015, Giuseppe Curigliano, MD, PhD, of Istituto Europeo di Oncologia, Milan, Italy, explains that…
At the European Cancer Congress (ECC) 2015, Riccardo A. Audisio, MD, FRCS, of the University of Liverpool, St. Helens Teaching…
Thomas Powles, MBBS, MRCP, MD, of Barts and The London School of Medicine and Dentistry, London, UK, discusses the results…
Can MPN patients develop biological markers that influence their current therapies? Yes, says MPN expert Dr. Srdan Verstovsek from The…
How has the field of MPNs expanded in the last 10 years? Meet MPN expert Dr. Laura Michaelis, Clinician and…
Fresh from the iwCLL, CLL expert Dr. William Plunkett, Professor in the Department of Experimental Therapeutics at The University of…
Can patient care be coordinated regardless of what country you live in? When should an MPN patient start seeking expert…
At the European Cancer Congress (ECC) 2015, David Ross Camidge, MD, PhD, of the University of Colorado Cancer Center, Aurora,…
At the European Cancer Congress (ECC) 2015, Wolfgang Janni, MD, PhD University Hospital Ulm, Ulm, discusses the interim analysis of…
Toni Choueiri, MD of the Dana-Farber Cancer Institute welcomes viewers to the 14th International Kidney Cancer Symposium 2015
Toni Choueiri, MD of the Dana-Farber Cancer Institute How Does the Axitinib Plus Pembrolizumab study impact future research?
Toni Choueiri, MD of the Dana-Farber Cancer Institute discusses the Phase Ib Dose-Finding Study of Axitinib Plus Pembrolizumab in Treatment-Naïve…
Michael Bassetti MD PhD of the University of Wisconsin Madison discusses the next steps Stereotactic Body Radiotherapy (SBRT) for Kidney…
Michael Bassetti MD PhD of University of Wisconsin Madison discusses What’s the Impact to Physicians Stereotactic Body Radiotherapy (SBRT) for…
Michael Bassetti MD PhD of the University of Wisconsin Madison discusses Stereotactic Body Radiotherapy (SBRT) for Kidney Cancer an Overview
Dr. Greco speaks about the usage of CancerTYPE ID to obtain a single diagnosis in patient with Cancer of Unknown…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute,…
At the European Cancer Congress (ECC) 2015, Paul Nathan, MB.BS, BSc (Hons), BA, PhD, FRCP, of Mount Vernon Cancer Centre,…
At the European Cancer Congress (ECC) 2015, Maria De Santis, MD, of the University of Warwick, Warwick, UK, discusses the…
At the European Cancer Congress (ECC) 2015, Giuseppe Curigliano, MD, PhD, of Istituto Europeo di Oncologia, Milan, Italy, discusses molecular…
At the European Cancer Congress (ECC) 2015, Matti Aapro, MD, of Clinique de Genolier, Genolier, Switzerland, describes the European School…
At the European Cancer Congress (ECC) 2015, Laurence Albiges, MD, of Institut Gustave Roussy, Villejuif, France, discusses the results of…
At the European Cancer Congress (ECC) 2015, Johan Vansteenkiste, MD, PhD, of KU Leuven, Leuven, Belgium, discusses the primary analyses…
At the European Cancer Congress (ECC) 2015, Grant McArthur, MBBS, BMedSc, PhD, FRACP, of the Peter MacCallum Cancer Centre, Victoria,…
At the European Cancer Congress (ECC) 2015, Eric Pujade-Lauraine, MD, PhD, of Université Paris Descartes, Assistance Publique-Hôpitaux de Paris, Paris,…
At the European Cancer Congress (ECC) 2015, Dirk Schadendorf, MD, PhD, of Universitätsklinikum Essen, Essen, Germany, discusses the advances in…
Multigene assays may provide clinically complementary information to classic clinicopathological tumour features, such as tumour size and grade, in breast…
The Oncotype DX® Breast Cancer Assay, a multigene assay, stratifies breast cancer patients into groups that are at low, intermediate…
At the European Cancer Congress (ECC) 2015, Benjamin Besse, MD, PhD, of Institut Gustave Roussy, Villejuif, France, discusses BIRCH, a…
At the European Cancer Congress (ECC) 2015, Bartomeu Massuti, MD, of Hospital General de Alicante, Alicante, Spain, discusses the Spanish…
At the European Cancer Congress (ECC) 2015, Georgina Long, BSc, PhD, MBBS, FRACP, of The University of Sydney, Sydney, Australia,…
@OncEd Presents Dr. Enriqueta Felip – Targeted therapies in ALK-positive NSCLC
@OncEd Presents Dr. Simon Raphael – Actionable biomarkers in NSCLC: EGFR and ALK
@OncEd Presents Dr. Keith Flaherty – Integrating new treatment options for melanoma
@OncEd Presents Dr. Keith Flaherty – An expert’s perspective on frequently asked questions on BRAF V600-mutated advanced melanoma
@OncEd Presents – Dr. Natasha Leighl & Dr. David Hogg – Immune Response Vs. RECIST Criteria
@OncEd Presents Dr. Lori Wood – Optimizing Outcomes in Advanced Prostate Cancer
Chris Carrigan of the National Cancer Intelligence Network (NCIN), discusses the uses of the enormous amount of data collected by…
Karen Kennedy, PhD, Director of the National Cancer Research Institute (NCRI), gives an overview of the 2015 NCRI Cancer Conference.…
Kristian Helin, PhD gives an overview of his talk on epigenetic targets in cancer presented at the 2015 National Cancer…
Robert Coleman, MBBS, MD, FRCP, a trustee of Breast Cancer Now, discusses the goals of the newly formed charity that…
Kevin Brindle, PhD gives an overview of his talk at the 2015 National Cancer Research Institute (NCRI) Cancer Conference, where…
Harpal Kumar, MA MEng MBA DSc gives an overview of his session at the 2015 National Cancer Research Institute (NCRI)…
Miriam Johnson, MD gives an overview of a session at at the 2015 National Cancer Research Institute (NCRI) Cancer Conference,…
With the advent of unlocking genetic code, the cancer community has now been introduced to the concept of immunotherapy. What…
In this segment of The Conversation, MPN Edition, Dr. Srdan Verstovsek of MD Anderson Cancer Center, MPN expert Dr. Mark…
CLL patients with certain genetic markers are considered to be high risk and their options for treatment have historically been…
MPN experts Dr. Mark Heaney of Columbia University Cancer Center and Dr. Srdan Verstovek of MD Anderson Cancer Center examine…
Dr. Michael Keating, a leading researcher from MD Anderson Cancer Center, has had a career that spans decades and has…
Paolo Boffetta, MD, MPH gives an overview of his talk at the 2015 National Cancer Research Institute (NCRI) Cancer Conference.…
Rebecca Fitzgerald, MD, FAAD gives an overview of a session presented at the 2015 National Cancer Research Institute (NCRI) Cancer…
Chad Creighton of the Baylor College of Medicine: “How does the Papillary RCC: The Cancer Genome Atlas (TCGA) impact Physicians?”
Chad Creighton of Baylor College of Medicine discusses the next steps for Papillary RCC: The Cancer Genome Atlas (TCGA)
Chad Creighton of Baylor College of Medicine discusses a short overview of the Papillary RCC: The Cancer Genome Atlas (TCGA)
Tim Hunt, FRS, FMedSci describes the path that led him to identify cyclin-dependent kinases (CDK), along with colleagues Paul Nurse…
Jack Cuzick, PhD, FMedSci, FRCP(hon), of the Queen Mary University of London, UK gives an overview of the session ‘Prevention…
In the session ” Tumour: stroma interactions” presented at the 2015 National Cancer Research Institute (NCRI) Cancer Conference, the importance…
Clare Turnbull, MD, PhD, gives an overview of her talk at the 2015 National Cancer Research Institute (NCRI) Cancer Conference,…
Neeraj Agarwal, MD of the Huntsman Cancer Institute presents “Molecular predictors of response and survival outcomes in patients with metastatic…
Michael A. Gorin, M.D. of Johns Hopkins University School of Medicine presents “Development of an Antibody-free Method for Detecting Renal…
David Gill, MD of the Huntsman Cancer Institute presents “Correlation of tumor programmed death ligand-1 (PD-L1) expression and response to…
Peter F. Thall, PhD of M.D. Anderson Cancer Center presents “Bayesian Designs for Early Phase Clinical Trials” at the 14th…
Meredith M. Regan, ScD of the Dana-Farber Cancer Institute presents “Statistical Considerations in RCC: Biomarker-Based Studies” at the 14th International…
Wayne A. Marasco, MD, Ph.D.of the Dana-Farber Cancer Institute presents “Carbonic Anhydrdase IX: Opportunities for Immune-Based Approaches” at the 14th…
Daniel Lindner, MD, PhD of the Cleveland Clinic presents “Patient derived xenograft models and ? potential therapeutic applications” at the…
Thai Ho, M.D., Ph.D. from the Mayo Clinic Arizona presents “The Evolving Role of Chromatin and Epigenetics in RCC” at…
Sumanta Kumar Pal, M.D. of the City of Hope Comprehensive Cancer Center presents “Applying Advanced Genomics to Therapy Selection” at…
Brian Rini, MD of the Cleveland Clinic presents “2015 Eugene P. Schonfeld Award” at the 14th International Kidney Cancer Symposium.
Eliezer (Eli) Van Allen, MD of Dana-Farber Cancer Institute presents “Expanding the clinically actionable kidney cancer genome” at the 14th…
Brian R. Lane, M.D., Ph.D., FACS of Spectrum Health Medical Group? presents “Molecular Prediction of Kidney Cancer Recurrence”
Thai Ho, M.D., Ph.D. from the Mayo Clinic Arizona presents “KCA Role in Developing a Research Program in Kidney Cancer…
André P. Fay, MD of Dana-Farbe presents “Treatment of Kidney Cancer in Developing Countries ” at the 14th International Kidney…
Thomas E Hutson, DO, PharmD, FACP of the Baylor-Sammons Cancer Center presents “Emerging Targeted Therapies” at the 14th International Kidney…
Laurence Albiges presents “Emerging Biomarkers of VEGF and mTOR Inhibitors in 2015” at the 14th International Kidney Cancer Symposium.
Daniel Y C Heng MD MPH FRCPC of the University of Calgary presents “Improving Patient Care Through Health Outcome Research…
Stacey Kenfield, DSc gives an overview of her talk at the 2015 National Cancer Research Institute (NCRI) Cancer Conference. Dr…
At the 2015 National Cancer Research Institute (NCRI) Cancer Conference, Justin Webb talks about the initiatives Macmillan Cancer Support is…
At the 2015 National Cancer Research Institute (NCRI) Cancer Conference, Justin Webb gives an overview of a new Macmillan Cancer…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute,…
At the European Cancer Congress (ECC) 2015, André Robidoux, MD, FRCSC, of Centre Hospitalier de l’Université de Montréal, Montreal, Canada,…
Judge Schonfeld-CEO-CureHunter Inc. presents “Speeding Drug Discovery with Computational Biology Network Graph Theory” at the 14th International Kidney Cancer Symposium.
John A. Josey, Ph.D. Peloton Therapeutics, Inc. presents “Targeting HIF-2: Myth or Reality? A First-In-Class HIF-2 Antagonist for the Treatment…
Jeffrey Wallin, Ph.D. of Genentech presents “Opening the Floodgates to T Cells Biomarkers for the Combination of Bevacizumab and Atezolizumab…
Fabian Zohren, MD PhD from Takeda presents “Inhibiting the mTOR Complex: Biology and Targets” at the 14th International Kidney Cancer…
Mark W Ball presents “Pathologic and Genomic Profiles of Exceptional Responders to Anti-PD1 Therapy in Renal Cell Carcinoma” at the…
Toni Choueiri, MD Dana-Farber Cancer Institute presents “Phase Ib Dose-Finding Study of Axitinib Plus Pembrolizumab in Treatment-Naïve PatientsWith Advanced Renal…
Michael Postow, MD from Memorial Sloan Kettering Cancer Center presents “Managing Side Effects of Immune Checkpoint Blockade” at the 14th…
Dan George, MD Duke Cancer Institute presents “Oncolytic Viruses” at the 14th International Kidney Cancer Symposium.
David McDermott, MD of Dana Farber presents “The Really Important Questions Current Immunotherapy Trials are Not Answering” at the 14th…
Ronit Simantov, M.D. of Pfizer Oncology presents “Optimizing Therapy of RCC through Industry-Academic Collaborations” at the 14th International Kidney Cancer…
Neeraj Agarwal, MD of Huntsman Cancer Institute, University of Utah presents “Initial therapy for mRCC: High-dose IL-2 or a Checkpoint…
Hans Hammers MD, PhD of Johns Hopkins presents “Initial Therapy for mRCC: Pro: Immune Checkpoint Inhibitors” at the 14th International…
Charles G. Drake MD of Johns Hopkins Kimmel Cancer Center presents Combination Immunotherapeutic Strategies in RCC: Preclinical Rationale AND Clinical…
Gordon Freeman, PhD from the Dana-Farber Cancer Institute Harvard Medical School presents “The Biology of Checkpoint Inhibition” at the 14th…
Moshe C. Ornstein MD MA of the Cleveland Clinic Taussig Cancer Institute presents “Clinical Effect of TKI Dose-Escalation after Disease…
Andrew J. Armstrong MD ScM FACP of Duke Cancer Institute presents “Clinical Trials in Non-Clear Cell RCC” at the 14th…
Jose A. Karam, MD, FACS of MD Anderson presents “RCC with Sarcomatoid Dedifferentiation: New Insights” at the 14th International Kidney…
Gabriel G. Malouf, MD, PhD of Pitie Salpetriere Hospital presents “Collecting Duct Renal Cell Carcinomas” at the 14th International Kidney…
Chad Creighton of Baylor College of Medicine presents “Papillary RCC: The Cancer Genome Atlas (TCGA)” at the 14th International Kidney…
Payal Kapur, M.D. of UT Southwestern Medical Center presents “Chromophobe Renal Cell Carcinoma: TCGA and UTSW Updates’ at the 14th…
Eric Jonasch Professor of Medicine UT MD Anderson Cancer Center presents “VHL Syndrome and Hemangioblastoma Management” at the 14th International…
Paul Russo, MD, FACS of Cornell University presents “Partial Nephrectomy 15 YEARS OF PROGRESS” at the 14th International Kidney Cancer…
Suzanne B. Stewart-Merrill. MD presents ” Oncologic Surveillance Following Surgical Resection for Renal Cell Carcinoma: A Novel Risk-based Approach” at…
Michael L. Blute Jr,. MD of the University of Wisconsin presents “Novel 3D volume analysis reveals primary tumor diameter is…
Sarah P. Psutka M.D., M.Sc of Cook County, Chicago presents “Management of Local Recurrence After Radical Nephrectomy” at the 14th…
E. Jason Abel, M.D. of the University of Wisconsin presents “Patient Selection for Surgery in RCC with Thrombus” at the…
Dipen J. Parekh, MD of the University of Miami Miller School of Medicine presents “WARMING UP TO ISCHEMIA” at the…
Karim Touijer , MD, MPH from the Memorial Sloan-Kettering Cancer Center presents “Partial Nephrectomy: Does Ischemia Matter?” at the 14th…
James Porter of the Swedish Medical Center Seattle, WA presents “Minimally Invasive Lymphadenectomy for Renal Cell Carcinoma” at the 14th…
Steven C. Campbell, MD, PhD of The Cleveland Clinic discusses “Optimal Treatment of cT1b Renal Mass in Patient with Normal…
Michael A. Gorin, M.D. of Johns Hopkins University School of Medicine discusses “Novel Imaging Techniques in RCC” at the 14th…
Michael Bassetti MD PhD of the University of Wisconsin Madison discusses “University of Wisconsin Madison” at the 14th International Kidney…
R. Houston Thompson, MD Professor of Urology Mayo Clinic discusses “Partial Nephrectomy or Ablation for Small Renal Mass” at the…
Michael A.S. Jewett discusses “Surveillance is the Best Treatment for T1a RCC in a healthy 65 year old patient” at…
Stephen A. Boorjian, MD of the Mayo Clinic, Rochester, MN discusses ” CONTEMPORARY MANAGEMENT OF RENAL ANGIOMYOLIPOMA” at the 14th…
Bradley C. Leibovich, MD, FACS , Mayo Clinic debates ” Renal Mass Biopsy Should Be Used Sparingly in patients with…
Tony Finelli, MD, MSc, FRCSC Head, Division of Urology GU Site Lead, Princess Margaret Cancer Center debates the Pro side…
A Ari Hakimi MD Memorial Sloan Kettering Cancer Center brings an “Update on Molecular and Genetic Characterization of RCC” at…
Brian R. Lane, M.D., Associate Professor, Michigan State University discusses “Improving Healthcare Delivery in Kidney Cancer” at the 14th International…
Dorothy Yang gives an overview of a study assessing the physical activity levels and barriers to exercise referral among patients…
James Larkin, MD, PhD gives an update on the clinical trial CheckMate 067, a phase 3 study of Nivolumab or…
Robert Thomas, MbChb, MRCP, MD, FRCR, gives an overview of the session “Physical activity the panacea?” at the 2015 National…
Prof. Rob Coleman gives an overview of the session “This house believes we should stop focussing on the causes of…
Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, discusses…
Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, gives…
Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, gives…
Previously, risk reduction from treatment with endocrine therapy has been represented as a general percentage for all patients treated. Knowing…
At the European Cancer Congress (ECC) 2015, André Robidoux, MD, FRCSC, of Centre Hospitalier de l’Université de Montréal, Montreal, Canada,…
At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses…
Dr. Naughton discusses the bothersome side effects and serious safety risks associated with endocrine therapy. He emphasizes the need to…
At the European Cancer Congress (ECC) 2015, Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research…
At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses…
At the European Cancer Congress (ECC) 2015, Riccardo A. Audisio, MD, FRCS, of the University of Liverpool, St. Helens Teaching…
@OncEd Presents Dr. Nancy Zhu – Case-Based Discussion for Managing MDS Patients. This live webinar took place on September 10,…
At the European Cancer Congress (ECC) 2015, Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research…
At the European Cancer Congress (ECC) 2015, Keith M. Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the University of Aberdeen,…
At the European Cancer Congress (ECC) 2015, Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research…
@OncEd Presents Dr. Martin Reck – ECC 2015 Immunotherapy Updates
@OncEd Presents Dr Luis Bruno – ECC 2015 GU Cancer Highlights (Portuguese Version)
@OncEd Presents Dr. Stephanie Snow – ECC 2015 Head and Neck Updates
@OncEd Presents Dr. Scott Berry – ICECREAM Trial
@OncED Presents Dr. Scott Berry – COMET Trial
@OncEd Presents Dr. Nadia Harbeck – PALOMA 3 Trial
@OncEd Presents Dr. Ralph Wong – Neuroendocrine Tumour Updates
@OncEd Presents Dr. Ramon Andrade de Mello – Hypermethylation of the TERT Promoter (Portuguese Version)
@OncEd Presents Dr. Ramon Andrade de Mello – Hypermethylation of the TERT Promoter
@OncEd Presents Dr. Silke Gillessen – SAKK 08/11 Study
@OncEd Presents Dr. Vladimir Milovanov – Predicting incomplete cytoreduction and aborted HIPEC in PC
@OncEd Presents Dr. Juan Pablo Marquez Manriquez – Multi-Antigen Vaccination for Colon Cancer Treatment and Prevention
@OncEd Presents Dr. Sunil Verma – ECC 2015 Breast Cancer Updates
@OncEd Presents Dr. Jeff Weber – Novel Combinations with Checkpoint Inhibitors